Seeking comments on interleukin 23 and its gut-skin-joint axis effects Looking for medical experts tha can comment on interleukin 23 and its gut-skin-joint axis effects.

Interleukin 23 is essentially the connective tissue of pro inflammatories in that it links the three systems of the gut-skin-joint axis. There are pro inflammatories that can affect specific systems, however, the ones that affect interrelated areas of the body can be particularly damaging and complicated. Interleukin 23 is one of the pro inflammatories that can be very damaging in that it can cause reactions within the gut through Th17 cell activation that disrupts intestinal barrier integrity, stimulates keratinocytes that can lead to skin conditions such as psoriasis and at the same time negatively impact joint health through those same triggers that cause bone erosion. It is the nature of Th17 cell activation and the keratinocytes that are part of its makeup that leads to chain reactions in these systems throughout the body, and can complicate treatments.

Dr. Sneha Sood, Dermatologist & Aesthetic Physician Interleukin-23 is an immune signaling molecule that plays an important role in chronic inflammatory conditions, particularly those affecting the skin. From a dermatology perspective, its relevance is most clearly seen in psoriasis, where IL-23 contributes to sustained immune activation. What has become increasingly clear in clinical practice is that IL-23-related inflammation is not limited to the skin alone. Many individuals with chronic inflammatory skin disease also experience joint symptoms or gastrointestinal involvement over time. This pattern reflects a shared immune pathway rather than separate, unrelated conditions, which is why the concept of a gut-skin-joint axis is widely discussed in medicine. In dermatology clinics, the skin often serves as the most visible indicator of broader immune activity. In some cases, skin symptoms appear earlier, while joint or digestive manifestations emerge later. Recognizing these patterns supports timely collaboration with other specialties, including gastroenterology and rheumatology, when appropriate. Overall, IL-23 helps illustrate how inflammatory processes can involve multiple organ systems simultaneously. Understanding this connection encourages a more integrated view of inflammatory disease, where the skin, joints, and gut are considered parts of the same immune network rather than isolated systems.

Dr. Ajay Kumar, Senior Gastroenterologist - Gut Clinic Interleukin-23 is an important immune mediator that helps explain why inflammatory conditions of the gut are frequently associated with skin and joint involvement. From a gastroenterology perspective, its role is most clearly recognized in chronic inflammatory bowel diseases, where IL-23 contributes to persistent intestinal immune activation. What we increasingly observe in clinical practice is that this inflammatory signaling does not remain confined to the gut. Patients with ongoing intestinal inflammation may also develop inflammatory skin conditions or joint symptoms over time. These manifestations reflect a shared immune pathway rather than independent diseases, which is why the concept of a gut-skin-joint axis has become well established. In many cases, gastrointestinal inflammation serves as an early driver of this process, even when digestive symptoms are mild or initially overlooked. As the same immune pathways remain active, inflammation can later appear in other organ systems. Recognizing this pattern helps clinicians avoid fragmented care and encourages timely collaboration with dermatology and rheumatology colleagues. Overall, IL-23 highlights the central role of the gut as an immune organ. Understanding how this pathway links intestinal, skin, and joint inflammation supports a more integrated approach to chronic inflammatory disease, focused on the underlying immune mechanisms rather than isolated symptoms.

Interleukin 23 (IL-23) plays a critical role in the gut-skin-joint axis by promoting inflammation and influencing immune system activity across these interconnected systems. It is a cytokine involved in driving Th17 cell differentiation, which contributes to the release of inflammatory mediators. Overactivity of IL-23 is implicated in several inflammatory conditions, such as psoriatic arthritis, inflammatory bowel disease (IBD), and psoriasis. On the gut level, IL-23 is known to disrupt gut barrier integrity, leading to increased inflammation and microbial imbalance. This dysfunction can trigger systemic immune responses, which may manifest in joint inflammation and skin lesions. Understanding IL-23's influence provides insight into targeted therapies such as IL-23 inhibitors, which have shown promise in managing these chronic, interrelated conditions.

Interleukin-23 (IL-23) plays a key role in connecting inflammation across the gut, skin, and joints by driving Th17 immune responses. When this pathway is overactive, it can contribute to conditions like inflammatory bowel disease, psoriasis, and psoriatic arthritis. The success of IL-23-targeting therapies across these diseases highlights how closely linked this gut-skin-joint inflammatory axis really is.

Interleukin-23 (IL-23) plays a pivotal role in the intricate gut-skin-joint axis, profoundly influencing inflammatory pathways. From a clinical perspective, dysregulation of IL-23 is linked to chronic conditions like psoriasis, inflammatory bowel disease (IBD), and ankylosing spondylitis. Addressing IL-23-mediated inflammation often uncovers latent connections between these systems. For instance, individuals presenting with chronic psoriasis may also report gastrointestinal disturbances, which, upon closer evaluation, reveal concurrent IBD. My experience shows that effective targeted therapies, such as IL-23 inhibitors, demonstrate substantial improvement in these interconnected symptoms, creating a ripple effect of physical and emotional relief. Understanding this axis is critical because holistic management of inflammatory processes not only alleviates individual symptoms but enhances overall quality of life.

Hi, I'm Dr Blen Tesfu, a physician and medical advisor at Welzo, where I focus on evidence-based insights related to immune health, chronic inflammation, and whole-body wellness. Here is my answer. IL-23 is an important mediator of the immune response that illustrates how inflammation originating in one organ system can have an impact on other organ systems; specifically, the gut, skin and joints. Elevated levels of IL-23 can promote the activation of Th17 cells, which are known to produce inflammation in multiple tissue systems, which is why IL-23 is referred to by many clinicians as being at the centre of what has come to be called the gut-skin-joint axis. Practically speaking, an imbalance of IL-23 can lead to conditions such as Crohn's disease, psoriasis, and some forms of inflammatory arthritis. Although these diseases may seem unrelated, all three are linked through their immune responses to IL-23 signalling. For example, patients with active gastrointestinal flare-ups often report experiencing simultaneous symptoms of skin lesions and/or arthralgias. The understanding of the mechanisms of IL-23 enables clinicians to evaluate inflammation as a multi-organ system condition versus a localised symptom-based illness. In addition, this knowledge helps clarify why treatments that target the IL-23 pathway may provide benefit to multiple areas of a patient's health simultaneously. Ultimately, IL-23 provides evidence of the true extent to which our immune systems interact and therefore emphasises the importance of determining the root cause of the inflammatory processes causing the symptoms.

Interleukin-23 sits upstream in a very specific inflammatory pathway that links the gut, skin, and joints. In my research background working with cytokines like IL-6, IL-3, and TNF-a, what becomes clear is that these molecules don't operate in isolation—they amplify one another. IL-23 is a key driver of Th17 cell activation, which then leads to downstream release of IL-17, TNF-a, and other pro-inflammatory mediators. Once that cascade is activated, you see parallel inflammatory signatures appearing across the gut epithelium, the skin, and synovial tissues. That's why IL-23 is so central to conditions that cluster across this axis: inflammatory bowel disease, psoriasis, and spondyloarthropathies. They share a common immunologic architecture. IL-23 supports survival and expansion of Th17 cells in the gut; those same cells circulate and create hyper-reactive responses in the skin and joints. When I worked with IL-6 and TNF-a models, we saw the same phenomenon: a single overactive pathway in the gut could mirror itself in peripheral tissues because the cytokine environment is systemic, not local. Blocking IL-23 interrupts the upstream signal rather than simply suppressing the downstream inflammation. That's why IL-23 inhibitors have been so effective—not just in resolving plaques in psoriasis, but in improving bowel symptoms and reducing joint inflammation in people who show involvement across multiple organ systems. The gut-skin-joint axis is really a reflection of immune redundancy. When IL-23 is overexpressed, the system doesn't just become inflamed in one place—it becomes primed everywhere that Th17-driven immunity plays a role. —Pouyan Golshani, MD | Interventional Radiologist & Founder, GigHz and Guide.MD | Los Angeles, CA

Interleukin-23 (IL-23) plays a key role in immune system regulation, particularly in inflammatory pathways. Recent studies suggest that IL-23 may influence the gut-skin-joint axis, which is the interconnected communication between gut microbiota, skin health, and joint function. Dysregulation of IL-23 has been linked to conditions like psoriasis, psoriatic arthritis, and inflammatory bowel disease. Experts believe that targeting IL-23 can help modulate inflammation across these systems, potentially improving symptoms in patients with overlapping gut, skin, and joint disorders. However, more clinical research is needed to fully understand its effects and therapeutic potential. Consulting a medical professional with experience in immunology or rheumatology is recommended for detailed insights.

Interleukin 23 (IL-23) plays a key role in what's often called the gut-skin-joint axis — the connection between gut inflammation, autoimmune skin diseases like psoriasis, and joint issues such as psoriatic arthritis. From my experience optimizing medical and health websites, I've worked closely with dermatologists and rheumatologists who highlight IL-23 as a driver of chronic inflammation. It acts like a signal amplifier — when the gut microbiome is imbalanced, IL-23 can trigger an immune response that doesn't stay localized. I've seen countless patient stories where improving gut health through diet or targeted biologics that block IL-23 led to visible improvements in skin and joint symptoms. One real example that sticks with me involved a clinic client whose psoriasis patients saw major relief after starting IL-23 inhibitors like guselkumab. Their results weren't just on the skin — they reported fewer gut flare-ups and reduced joint stiffness. That experience taught me how deeply the immune system connects these body systems. For readers, the key takeaway is that managing inflammation holistically — from gut to skin to joints — is far more effective than treating each symptom in isolation. Keeping your gut healthy through balanced nutrition, probiotics, and minimizing triggers like stress or processed foods can make a tangible difference in inflammatory conditions influenced by IL-23.

I have worked with thousands of patients who are suffering from inflammatory or auto-immune disorders using functional medicine principles. IL-23 is a messenger protein that promotes inflammatory processes within multiple organ systems of the body simultaneously. Once activated, IL-23 stimulates a particular type of immune cell known as Th17 cells, these cells create additional inflammatory messengers that induce inflammation of the barrier tissues in the body. The gut lining, the skin and the joint capsules have structural properties that allow them to be affected similarly by an IL-23 driven inflammatory cascade. Once it is understood how IL-23 disrupts tight junction proteins in the intestinal barrier, allowing bacteria and food particles to enter the blood stream and stimulate an immune response that manifests itself as skin inflammation and joint swelling, the relationship between the gut, skin and joints becomes apparent. Because of its systemic nature, elevated IL-23 levels result in symptoms affecting all three areas. In order to manage IL-23 induced inflammation, one must view the inflammatory cascade as a continuum, rather than separate components. Therefore, dietary changes that enhance gut barrier function combined with anti-inflammatory strategies that target the inflammatory cascade can reduce the production of IL-23 related inflammatory mediators. Rather than merely managing symptoms in individual tissues, the ultimate goal is to suppress the initial immune stimulus.

Interleukin-23 (IL-23) has emerged as the "master regulator" of the gut-skin-joint axis, serving as the critical link between mucosal immunity and systemic inflammation. Its role is best understood through the IL-23/Th17 pathway, where it drives the differentiation and survival of Th17 cells and innate lymphoid cells (ILC3s). The Mechanistic Link: The "axis" operates on the premise that inflammation often originates at barrier surfaces. In the gut, microbiome dysbiosis can trigger local IL-23 production. These activated immune cells do not remain locally confined; they can migrate to distant sites specifically the skin and joints or trigger systemic cytokine cascades. 1. Gut: IL-23 is pivotal in maintaining intestinal homeostasis, but its dysregulation drives the pathogenesis of Inflammatory Bowel Disease (IBD), particularly Crohn's disease. It acts as a bridge, translating microbial cues into an inflammatory response. 2. Skin: In the skin, IL-23 stimulates Th17 cells to release IL-17A and IL-22, leading to the keratinocyte hyperproliferation and plaque formation characteristic of psoriasis. 3. Joints: Crucially, IL-23 is a key driver of enthesitis (inflammation at tendon insertion sites), which is the primary pathology in Psoriatic Arthritis (PsA) and Spondyloarthritis. Residents cells at the enthesis are highly responsive to IL-23, leading to local bone erosion and new bone formation. Clinical Implications: The validation of this axis is evident in therapeutic outcomes. Biologics that selectively inhibit the p19 subunit of IL-23 (e.g., guselkumab, risankizumab) have demonstrated high efficacy not just in clearing psoriatic skin lesions, but also in resolving enthesitis and inducing remission in Crohn's disease. This confirms that targeting the apical IL-23 node offers a comprehensive approach to treating the multifaceted psoriatic and spondyloarthropathic spectrum.

Interleukin-23 is interesting because it sits at a crossroads between the immune system and barrier tissues. What makes IL-23 especially relevant to the gut-skin-joint axis is that it helps sustain Th17 immune responses, which are protective in short bursts but inflammatory when chronically activated. One pattern researchers keep seeing is that IL-23-driven inflammation often begins at barrier sites like the gut. When the intestinal lining becomes more permeable—sometimes referred to as "leaky gut"—immune signaling doesn't stay local. IL-23 can amplify inflammatory pathways that later show up systemically, contributing to conditions where gut symptoms coexist with skin inflammation (such as psoriasis) and joint involvement (such as psoriatic arthritis). What's notable is that IL-23 doesn't act alone. It functions more like a volume knob than an on/off switch, intensifying immune signals that are already present. That helps explain why targeting IL-23 has shown benefits across multiple tissues rather than just one isolated symptom area. From a broader perspective, the IL-23 gut-skin-joint connection highlights a shift in how inflammatory diseases are understood: not as single-organ problems, but as networked immune conditions. For researchers and clinicians, this reinforces the importance of early gut health signals when evaluating chronic inflammatory disorders elsewhere in the body.

Interleukin-23 (IL-23) is a key pro-inflammatory cytokine that links inflammation of the gut, skin, and joints through shared type-17 immune pathways. Produced mainly by dendritic cells and macrophages, IL-23 sustains Th17 and innate-like lymphocytes that secrete IL-17 and IL-22, cytokines central to chronic inflammation at barrier tissues. In the gut, IL-23-driven responses to microbial dysbiosis contribute to intestinal inflammation and may precede or amplify systemic disease; in the skin, IL-23 is a dominant driver of psoriasis by promoting keratinocyte hyperproliferation and inflammatory cell recruitment; and in the joints and entheses, IL-23 contributes to inflammation and abnormal bone remodeling, particularly in psoriatic arthritis, though its role is less consistent in axial spondyloarthritis. The frequent coexistence of inflammatory bowel disease, psoriasis, and inflammatory arthritis reflects a shared immunopathogenic network rather than isolated organ-specific diseases. Recognition of this gut-skin-joint axis supports a holistic but tissue-specific approach to diagnosis and treatment, as demonstrated by the efficacy of IL-23-targeted therapies in selected immune-mediated inflammatory diseases.

Interleukin-23 has become the "master switch" of the gut-skin-joint axis because it sits upstream of the Th17 pathway that drives psoriasis, psoriatic arthritis and several forms of inflammatory bowel disease. IL-23 is produced at barrier sites like the gut and skin; when dysbiosis or injury keeps that signal turned on, the same pro-inflammatory T cells that damage the intestinal lining can also traffic to the skin and entheses, explaining why psoriasis, IBD and spondyloarthritis so often travel together in the same patient. What makes IL-23 so compelling is that the biology and the bedside data now line up: selective IL-23 inhibitors improve plaques, joints and bowel symptoms in parallel, which is pretty rare in immunology and a strong clue that we are genuinely hitting a shared upstream node rather than just treating organ by organ. I think of IL-23 as the immune system's overcaffeinated project manager at barrier tissues; when it overshoots, you do not just get a skin disease or a gut disease, you get a systemic "barrier disease" that happens to show up in the organ that is most vulnerable for that person. Albert Richer, Founder, WhatAreTheBest.com

IL-23 is a signaling protein that helps drive a specific inflammatory pathway, and when it stays overactive it can push immune cells toward ongoing inflammation. That "gut skin joint axis" framing shows up because immune activity in the gut can spill into systemic inflammation, which can affect skin and joints in conditions like psoriasis and psoriatic arthritis, and IL-23 is one of the targets used in modern biologic therapies. A practical takeaway is that these systems are connected through shared immune signaling and barrier health, so symptoms in one area can track with flares in another. For the piece, I'd encourage quoting a clinician on where the evidence is strongest, what's still debated, and how this affects treatment choices and monitoring.

Shamsa Kanwal, M.D., is a Medical Dcotor with over 10 years of clinical experience. She currently practices at https://www.myhsteam.com/(USA) Profile link: https://www.myhsteam.com/writers/6841af58b9dc999e3d0d99e7 My take on your question is given below: Interleukin 23 (IL 23) is a key immune messenger that helps drive the Th17 pathway, which is central to inflammation in the gut, skin, and joints. When IL 23 is overactive, it can promote diseases like psoriasis on the skin, inflammatory bowel disease in the gut, and psoriatic arthritis in the joints, which is why we talk about a shared gut skin joint axis. As per my experience, patients with psoriasis often have family or personal histories of gut and joint issues, and IL 23 targeting biologics can improve plaques and joint pain together, which supports this connection in real life. For patients, this means that persistent rashes, digestive symptoms, and joint pain should not be viewed in isolation, and a coordinated care plan with dermatology, rheumatology, and gastroenterology can help catch IL 23 driven disease earlier and improve quality of life.

Interleukin-23 (IL-23) has been identified as a key cytokine for the gut-skin-joint axis that connects the immune responses in these different organs. IL-23 has a central role in the generation of inflammation through the survival and proliferation of Th17 cells, which secrete pro-inflammatory cytokines. This throughway accounts for why diseases like IBD, psoriasis, and psoriatic arthritis tend to bunch together. In the intestine, IL-23 plays a role in sustaining chronic inflammation by perturbing mucosal barrier function and promoting autoimmunity. Patients with Crohn's disease, for instance, are often found to have increased IL-23 activity that is associated with disease severity. In the skin, IL-23 activates keratinocytes and sustains the loop of inflammation characteristic of psoriasis. This results in visible lesions and systemic inflammation that may reach beyond the skin. Within the joints, IL-23-mediated Th17-associated responses play a role in synovial inflammation and bone damage (especially in psoriatic arthritis). The association of gut dysbiosis, cutaneous manifestations, and arthritis reflects IL-23 as a "bridge cytokine" of these systems. Clinically, IL-23 blockade (biologics against the p19 subunit) has been extremely effective in psoriasis and psoriatic arthritis, and some evidence is emerging for efficacy across the IBD spectrum. This highlights the clinical significance of IL-23 and its targeted treatment in related inflammatory diseases. What makes IL-23 so interesting, the implication of all this work is that if we can target one organ of immune dysregulation with these targeted agents in the clinic, and sort out what other organs are influenced by their presence! Knowledge of this axis allows clinicians to anticipate comorbidities and personalize therapies directed at systemic inflammation rather than individual symptoms.